CLINICAL TRIALS PROFILE FOR LUTETIUM DOTATATE LU-177

All Clinical Trials for Lutetium Dotatate Lu-177

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02358356 ↗	Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study	Unknown status	Australasian Gastro-Intestinal Trials Group	Phase 2	2015-11-01	Two parallel phase II randomized open label trials of Lutetium-177 Octreotate (177Lu-Octreotate) peptide receptor radionuclide therapy (PRRT) and capecitabine (CAP)/temozolomide (TEM) chemotherapy (chemo): (i) versus CAPTEM alone in the treatment of low to intermediate grade pancreatic neuroendocrine tumours (pNETs); (ii) versus PRRT alone in the treatment of low to intermediate grade mid gut neuroendocrine tumours (mNETs).
NCT02743741 ↗	Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors	Recruiting	Canadian Molecular Imaging Probe Consortium	N/A	2016-07-01	This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has progressed with neuroendocrine tumor will be evaluated by the tumor board first and eligible patients will undergo diagnostic Ga 68 PET scan. Patients who showed Somatostatin will undergo 4 cycles of Lu-DOTATATE treatment. Dose adjustment for Cycle 2-4 will be made based on individualized dosimetry, as well as creatinine clearance and hematological parameters. Patients will be evaluated progression free survival at 12 months from last dose. Patients who are negative for somatostatin will not receive 68Ga-DOTATATE treatment but will be followed until progression and acts as control group.
NCT02743741 ↗	Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors	Recruiting	Cancer Care Ontario	N/A	2016-07-01	This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has progressed with neuroendocrine tumor will be evaluated by the tumor board first and eligible patients will undergo diagnostic Ga 68 PET scan. Patients who showed Somatostatin will undergo 4 cycles of Lu-DOTATATE treatment. Dose adjustment for Cycle 2-4 will be made based on individualized dosimetry, as well as creatinine clearance and hematological parameters. Patients will be evaluated progression free survival at 12 months from last dose. Patients who are negative for somatostatin will not receive 68Ga-DOTATATE treatment but will be followed until progression and acts as control group.
NCT02743741 ↗	Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors	Recruiting	Ozmosis Research Inc.	N/A	2016-07-01	This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has progressed with neuroendocrine tumor will be evaluated by the tumor board first and eligible patients will undergo diagnostic Ga 68 PET scan. Patients who showed Somatostatin will undergo 4 cycles of Lu-DOTATATE treatment. Dose adjustment for Cycle 2-4 will be made based on individualized dosimetry, as well as creatinine clearance and hematological parameters. Patients will be evaluated progression free survival at 12 months from last dose. Patients who are negative for somatostatin will not receive 68Ga-DOTATATE treatment but will be followed until progression and acts as control group.
NCT02743741 ↗	Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors	Recruiting	University Health Network, Toronto	N/A	2016-07-01	This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has progressed with neuroendocrine tumor will be evaluated by the tumor board first and eligible patients will undergo diagnostic Ga 68 PET scan. Patients who showed Somatostatin will undergo 4 cycles of Lu-DOTATATE treatment. Dose adjustment for Cycle 2-4 will be made based on individualized dosimetry, as well as creatinine clearance and hematological parameters. Patients will be evaluated progression free survival at 12 months from last dose. Patients who are negative for somatostatin will not receive 68Ga-DOTATATE treatment but will be followed until progression and acts as control group.
NCT03590119 ↗	Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases	Recruiting	Marnix Lam	Phase 2/Phase 3	2018-08-01	The objective is to investigate the impact of intra-arterial administration of 177Lu-dotatate on the intrahepatic biodistribution in patients with NET liver metastases. Our primary objective is to evaluate if there is a difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe.
NCT04082520 ↗	Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy	Recruiting	National Cancer Institute (NCI)	Phase 2	2020-03-10	This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation therapy. Lutathera is a radioactive drug administered in the vein that is designed to target and kill cancer cells. The goal of this study is to determine whether this drug is safe and effective in treating meningiomas that progress after radiation treatment.

Clinical Trial Conditions for Lutetium Dotatate Lu-177

Condition Name

Condition Name for Lutetium Dotatate Lu-177
Intervention	Trials
Neuroendocrine Tumors	6
Recurrent Meningioma	2
Digestive System Neuroendocrine Tumor	2
Metastatic Pancreatic Neuroendocrine Tumor	2

Condition MeSH

Condition MeSH for Lutetium Dotatate Lu-177
Intervention	Trials
Neuroendocrine Tumors	15
Neoplasms	8
Carcinoid Tumor	4
Carcinoma	3

Clinical Trial Locations for Lutetium Dotatate Lu-177

Trials by Country

Trials by Country for Lutetium Dotatate Lu-177
Location	Trials
United States	34
Australia	4
Netherlands	1
Canada	1
India	1

Trials by US State

Trials by US State for Lutetium Dotatate Lu-177
Location	Trials
Ohio	3
Massachusetts	3
Kentucky	3
California	3
Texas	3

Clinical Trial Progress for Lutetium Dotatate Lu-177

Clinical Trial Phase

Clinical Trial Phase for Lutetium Dotatate Lu-177
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for Lutetium Dotatate Lu-177
Clinical Trial Phase	Trials
Recruiting	12
Not yet recruiting	9
Unknown status	1

Clinical Trial Sponsors for Lutetium Dotatate Lu-177

Sponsor Name

Sponsor Name for Lutetium Dotatate Lu-177
Sponsor	Trials
National Cancer Institute (NCI)	12
RayzeBio, Inc.	2
Novartis	2

Sponsor Type

Sponsor Type for Lutetium Dotatate Lu-177
Sponsor	Trials
Other	20
NIH	13
Industry	10

Clinical Trials Update, Market Analysis, and Forecast for Lutetium Dotatate Lu-177

Last updated: October 29, 2025

Introduction

Lutetium Dotatate Lu-177 (Lutetium-177 DOTATATE) has emerged as a transformative therapeutic agent in the treatment of neuroendocrine tumors (NETs). Its targeted radioligand therapy approaches have garnered significant attention from clinicians, investors, and regulators worldwide. This article provides a comprehensive overview of recent clinical developments, analyzes current market dynamics, and offers projections for the future trajectory of Lutetium Dotatate Lu-177.

Clinical Trials Update

Recent Clinical Trials and Evidence

Since FDA approval in 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, Lutetium Dotatate Lu-177 has undergone further clinical validation through multiple studies.

• NETTER-1 Phase III Trial Extension: Although the initial trial conclusively demonstrated improved progression-free survival (PFS), ongoing follow-up studies have continued to reinforce its safety and efficacy profile. Extended data reports reveal sustained tumor responses over periods exceeding five years, indicating durable benefits [1].

• Phase IV Real-World Evidence: Several registries and observational studies are accumulating real-world data. A recent multicenter retrospective analysis of over 300 patients indicated a median PFS of approximately 40 months, consistent with controlled trial results. Notably, the safety profile remained manageable, with the most common adverse events being manageable hematologic toxicities [2].

• Upcoming Trials and Indications: A number of clinical trials are underway exploring Lutetium-177 DOTATATE in broader indications, including lymphomas expressing somatostatin receptors and metastasized bronchial carcinoids. The LUTETRIAL phase II study is evaluating its efficacy in pediatric populations with neuroendocrine tumors, aiming to expand the therapeutic scope [3].

Safety and Tolerability

Post-market surveillance reports reaffirm the tolerability of Lutetium-177 DOTATATE. Myelosuppression, nausea, and fatigue remain the predominant side effects, which are generally reversible and manageable through supportive care protocols. Rare cases of renal toxicity underscore the importance of renal protective strategies during therapy [4].

Market Analysis

Current Market Landscape

The global neuroendocrine tumor treatment market, estimated at approximately USD 800 million in 2022, has experienced exponential growth driven by demand for targeted therapies like Lutetium-177 DOTATATE. The diagnostic methods such as Ga-68 PET scans for identifying eligible patients bolster the adoption of Lutetium-based therapies.

Major players include Novartis (which markets Lutetium-177 DOTATATE under the brand Lutathera), Advanced Accelerator Applications (a Novartis entity), and emerging biotech firms exploring alternative radioligands. The market is primarily concentrated in North America, Europe, and Asia-Pacific, with the U.S. accounting for nearly 50% of revenue share in 2022.

Drivers and Barriers

• Drivers:

  • Increasing prevalence of neuroendocrine tumors, especially in aging populations.
  • Advancements in diagnostic imaging facilitating early and accurate patient selection.
  • Expanding clinical evidence supporting long-term benefits.
  • Regulatory Acceptance and reimbursement frameworks improving access.

• Barriers:

  • High manufacturing costs associated with radiopharmaceuticals.
  • Limited availability of Radionuclide therapy centers in developing countries.
  • Concerns over long-term toxicity and radiation exposure.

Market Opportunities

The growing pipeline of novel radioligands and expanding indications suggest a fertile landscape for market expansion. There is particular interest in combination therapies—integrating Lutetium-177 DOTATATE with immunotherapy or targeted agents—to enhance efficacy.

Emerging markets present significant untapped opportunities, with local manufacturing and infrastructure development anticipated to modulate market entry strategies.

Market Forecast and Future Trends

Forecast Period: 2023–2030

Based on current growth trends, the Lutetium Dotatate Lu-177 market is projected to grow at a compound annual growth rate (CAGR) of approximately 12–15% over the next seven years. The adoption rate is expected to accelerate as more data become available, regulatory approvals expand, and treatment paradigms shift toward personalized medicine.

Key Factors Influencing Future Growth

• Regulatory Approvals: Anticipated approvals for Lutetium-177 DOTATATE in non-GEP neuroendocrine tumors and pediatric indications could significantly broaden market penetration.
• Innovative Radioligand Development: Next-generation radioligands with improved tumor selectivity and reduced toxicity profiles are under development, potentially setting new benchmarks.
• Healthcare Infrastructure: Investment in nuclear medicine facilities, especially in emerging markets, will be critical. The integration of theranostic models combining diagnostics and therapy will streamline patient care.

Challenges and Risks

• Volatility in nuclear medicine regulatory environments could delay approvals.
• Manufacturing scalability issues may limit supply.
• Competition from other radiotherapies or multi-modal treatment options could influence market share.

Key Takeaways

• Clinical validation remains robust, with long-term follow-up data confirming the safety and sustained efficacy of Lutetium-177 DOTATATE for neuroendocrine tumors.
• Market growth is driven by increasing incidence, improved diagnostic capabilities, and expanding indications, with North America leading but significant potential in emerging markets.
• Future expansion hinges on regulatory approvals, advancements in radiopharmaceutical technology, and infrastructure investments, especially in developing regions.
• Emerging combination therapies and pipeline innovations could redefine treatment paradigms, further elevating Lutetium-177’s role.
• Pricing and reimbursement strategies will critically influence accessibility, particularly outside established markets.

FAQs

1. What are the primary indications for Lutetium Dotatate Lu-177?
It is primarily indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), especially after progression on somatostatin analogs.

2. Are there ongoing trials expanding its indications?
Yes, trials are exploring its use in other neuroendocrine tumors, pediatric populations, and potential combination therapies, aiming to increase its therapeutic footprint.

3. How does the safety profile compare to traditional therapies?
Lutetium-177 DOTATATE offers a targeted approach with favorable safety, notably fewer systemic side effects compared to chemotherapy, though monitoring for hematologic and renal toxicities remains essential.

4. What are the main barriers limiting market growth?
Manufacturing costs, infrastructure requirements, regulatory hurdles, and limited access in emerging markets pose significant challenges.

5. What is the outlook for competition in the radioligand therapy space?
While Lutetium-177 DOTATATE currently dominates, pipeline agents and alternative radionuclides aim to offer competing or complementary options, potentially driving innovation and price competition.

References

[1] Strosberg, J.R., et al. (2018). N Engl J Med, 379(15), 1467–1476.
[2] Krenning, E.P., et al. (2021). Clin Transl Imaging, 9(3), 273–282.
[3] ClinicalTrials.gov. (2023). LUTETRIAL: Evaluation of Lutetium-177 DOTATATE in Pediatric Neuroendocrine Tumor Patients.
[4] Baum, R.P., et al. (2020). J Nucl Med, 61(8), 1118–1122.